The economics of follow-on drug research and development: Trends in entry rates and the timing of development

PharmacoEconomics

Volumn 22, Issue SUPPL. 2, 2004, Pages 1-14

  DiMasi, Joseph A ^a   Paquette, Cherie ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUPENT SYRUP; ANTHELMINTIC AGENT; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFALEXIN; CEFRADINE; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; CYTARABINE; DAUNORUBICIN; DIAZEPAM; DOXORUBICIN; ETACRYNIC ACID; FIBRIC ACID DERIVATIVE; FLOXURIDINE; FUROSEMIDE; GEMFIBROZIL; ISOTRETINOIN; LOOP DIURETIC AGENT; MEBENDAZOLE; METOPROLOL TARTRATE; NALIDIXIC ACID; ORPHAN DRUG; OXAZEPAM; OXOLINIC ACID; POTASSIUM SPARING DIURETIC AGENT; PRAZOSIN; PROPRANOLOL; PYRIMIDINE NUCLEOSIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOIC ACID; RIFABUTIN; RIFAMPICIN; SPIRONOLACTONE; TAMOXIFEN CITRATE; TERAZOSIN; TERBUTALINE; TIABENDAZOLE; TRIAMTERENE; UNINDEXED DRUG; UTIBID;

COMPETITION; CONFERENCE PAPER; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG COST; DRUG DESIGN; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; DRUG SCREENING; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; PATENT; PRIORITY JOURNAL;

EID: 8344266043     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422002-00002     Document Type: Conference Paper

References (30)

1. Wastila LJ, Ulcickas ME, Lasagna L. The World Health Organization's essential drug list. J Clin Res Drug Dev 1989; 3: 105-15
2. Kemp BA. The follow-on development process and the market for diuretics. In: Helms RB, editor. Drug development and marketing. Washington, DC: American Enterprise Institute, 1975
3. Werthheimer A, Levy R, O'Connor T. Too many drugs? The clinical and economic value of incremental innovations. In: Research in human capital and development. Vol. 14, Investing in Health: The Social and Economic Benefits of Health Care Innovation., Sorkin A, Summers K, Farquhar, eds., Greenwich, Conn: JAI Press, 2001: 77-118
4. Lu ZJ, Comanor WS. Strategic pricing of new pharmaceuticals. Rev Econ Stat 1998; 80 (1): 108-18
5. Towse A, Leighton T. The changing nature of NCE pricing of second and subsequent entrants. In: Sussex J, Marchant N, editors. Risk and return in the pharmaceutical industry. London: Office of Health Economics, 1999 Aug: 91-105
6. DiMasi JA. Price trends for prescription pharmaceuticals: 1995-1999, a background report prepared for the Department of Health and Human Services, August 8-9, 2000[online]. Available from URL: http://aspe.hhs.gov/health/ reports/Drug-papers/dimassi/dimasi-final.htm [Accessed September 14, 2004]
7. Lee TH. 'Me-too' products: friend or foe? N Engl J Med 2004; 350: 211-2
8. Agarwal R, Gort M. First-mover advantage and the speed of competitive entry, 1887-1986. J Law Econ 2001: 44 (April): 161-77
9. Bain JS. Barriers to new competition. Cambridge (MA): Harvard University Press, 1956
10. Kettler HE. Competition through innovation, innovation through competition. London: Office of Health Economics, 1998 Nov
11. Scrip's yearbook. Richmond, UK: PJB Publications, 1987-2003
12. Grabowski HG, Vernon J, DiMasi JA. Returns on R&D for 1990s new drug introductions. Pharmacoeconomics 2002; 20 Suppl. 3: 11-29
13. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22 (2): 151-85
14. DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001; 69 (5): 297-307
15. DiMasi JA. New drug development in the United States: 1963-1999. Clin Pharmacol Ther 2001; 69 (5): 286-96
16. Lichtenberg FR, Philipson TJ. The dual effects of intellectual property regulations: within- and between-patent competition in the US pharmaceuticals industry. National Bureau of Economic Research Working Paper Series, October 2002, Working Paper 9303 [online]. Available from URL: http://www.nber.org/ papers/w9303.pdf [Accessed September 14, 2004]
17. Cockburn IM. The changing structure of the pharmaceutical industry. Health Aff 2004 Jan/Feb; 23 (1): 10-22
18. DiMasi JA. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. Drug Inf J 2000; 34 (4): 1169-94
19. Danzon PM, Pauly MV. Health insurance and the growth in pharmaceutical expenditures. J Law Econ 2002; 45 (Oct-): 587-613
20. Baumol WJ. The free-market innovation machine: analyzing the growth miracle of capitalism. Princeton and Oxford: Princeton University Press, 2002: 33
21. Lichtenberg FR. Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. Health Aff 2001 Sep/Oct; 20 (5): 241-51
22. Lichtenberg FR. Benefits and costs of newer drugs. National Bureau of Economic Research Working Paper Series, June 2002, Working Paper 8996 [online]. Available from URL: http://www.nber.org/papers/w8996.pdf [Accessed September 14, 2004]
23. Lichtenberg FR. The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001. National Bureau of Economic Research Working Paper Series, June 2003, Working Paper 9754 [online]. Available from URL: http://www.nber.org/papers/w9754.pdf [Accessed September 14, 2004]
24. Angell M. The pharmaceutical industry: to whom is it accountable? New Engl J Med 2000; 342 (25): 1902-4
25. Relman AS, Angell M. America's other drug problem: how the drug industry distorts medicine and politics. The New Republic 2002; 587 (4); 27-41
26. Editorial. Comparing prescription drugs. New York Times 2003 Aug 27; Sect. A: 20
27. Goozner M. Prescription for reform. Washington Post 2003 Dec 1; Sect. A: 23
28. F-D-C Reports. AHRQ comparative study agenda should emphasize lit reviews - McClellan. Pink Sheet 2004 May 31; 66 (22): 26-7
29. Henderson R, Cockbura I. Scale, scope, and spillovers: the determinants of research productivity in drug discovery. RAND J Econ Spring 1996; 27 (1): 32-59
30. F-D-C Reports. CMS will focus on value, not price, of medicines, McClellan pledges. Pink Sheet 2004 Mar 29; 66 (13): 9-10